Enveric Biosciences Stock Surges After Trump Executive Order on Psychedelics
20 Apr 2026 · 14:13 UTC · CoinCentral RSS Feed · Original source
Read original at CoinCentral RSS Feed →
Summary
President Trump signed an executive order directing health regulators to fast-track the review and approval of psychedelic drugs for medical use. The order aims to accelerate clinical trials and regulatory processes for psychedelic-assisted therapies. Trump committed $50 million in federal funding to ibogaine research, a Schedule I controlled substance being studied for potential therapeutic applications. The announcement triggered a broad rally in the psychedelic biotech sector. Enveric Biosciences (ENVB), a biotech company focused on psychedelic drug development, experienced a major stock surge, rising over 160% following the news. The order reflects growing political support for reconsidering the regulatory status of psychedelics as clinical evidence of their therapeutic potential accumulates.
Why it matters
The fundamental disconnect is clear: psychedelic drug policy affects biotech firms and traditional pharmaceutical markets, not blockchain or cryptocurrency ecosystems. ENVB is a conventional equity on traditional exchanges; its 160% surge reflects investor enthusiasm for psychedelic-assisted therapies, not crypto adoption, regulation, or technical developments. The only theoretical transmission mechanism to crypto would be through macro risk sentiment—if biotech optimism signals broader risk-on markets, crypto might see modest tailwinds as a risk asset. However, this connection is tenuous, historically inconsistent, and insufficient to generate measurable directional impact. The article's placement on a crypto outlet appears to be editorial scope creep rather than substantive digital asset news. Confidence in meaningful Bitcoin or altcoin price movement is very low (0.10–0.15) across all timeframes.
Expected impact
This article reports on Trump's executive order to fast-track psychedelic drug reviews and a $50 million commitment to ibogaine research, which triggered a significant rally in biotech equities including Enveric Biosciences (ENVB, up 160%). However, this news has virtually no direct impact on cryptocurrency markets. While published on CoinCentral, the article concerns pharmaceutical regulation and biotech equity performance, not blockchain technology or digital asset fundamentals. Any potential crypto market effects would be extremely indirect and negligible—mediated only through loose macro sentiment channels (risk-on appetite following positive traditional finance news). For both BTC and altcoins, expected measurable price impacts are minimal across all timeframes, with impact probabilities consistently below 0.15.